Boundless Bio(BOLD.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Boundless Bio
BOLD.US
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company’s lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models. In addition, the company offers ECHO, an ecDNA harboring oncogenes diagnostic test to detect ecDNA in patient tumor specimens; and Spyglass platform, a platform used to identify druggable targets in oncogene amplified cancers.
1.880 T
BOLD.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Boundless Bio CEO to Join Fireside Chat at Piper Sandler Healthcare Conference

    Boundless Bio Inc.'s CEO, Zachary Hornby, will join a fireside chat at the Piper Sandler Healthcare Conference on December 3, 2025, in New York. The event will be webcast live and archived on the company's website. This news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    BOLD
    -0.80%
    Reuters·
    US
    BOLD
    -0.80%

    Boundless Bio Unveils New Therapies Targeting ecDNA-Driven Cancer

    Boundless Bio Inc. has introduced new ecDNA-directed therapies (ecDTx) aimed at treating oncogene amplified cancers, which lack effective existing treatments. Their clinical-stage candidates include BBI-355 and BBI-825, currently in the POTENTIATE trial, and BBI-940, set to enter trials in 2026. With 25% of cancer patients having amplified oncogenes, this approach addresses a significant medical need. The full presentation is available via a provided link.

    Reuters·
    US
    BOLD
    -0.80%
    Reuters·
    US
    BOLD
    -0.80%

    Boundless Bio Inc. Reports Q3 2025 Financial Results

    Boundless Bio Inc. (BOLD) reported its Q3 2025 financial results, showing a net loss of $13.9 million, an improvement from $16.5 million in Q3 2024. The company, focused on therapies for oncogene-amplified cancers, is advancing its pipeline, including ongoing enrollment in the POTENTIATE trial and plans for a first-in-human trial for BBI-940 in 2026. With $117.6 million in cash, Boundless Bio aims to deliver proof-of-concept data while maintaining a robust cash position through mid-2028, remaining optimistic about its impact on patients and shareholders.

    Tip Ranks·
    US
    BOLD
    -0.80%
    Tip Ranks·
    US
    BOLD
    -0.80%

    Boundless Bio | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    BOLD
    -0.80%
    LB filings·
    US
    BOLD
    -0.80%

    Boundless Bio | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    BOLD
    -0.80%
    LB filings·
    US
    BOLD
    -0.80%
    © 2026 Longbridge｜Disclaimer